Home » Roche, C4 Team Up to Develop Targeted Protein Degradation Treatments
Roche, C4 Team Up to Develop Targeted Protein Degradation Treatments
January 14, 2016
C4 Therapeutics will partner with Swiss drug giant Roche to develop novel treatments in the field of targeted protein degradation.
The agreement — worth up to $750 million — will use C4’s Degronimid technology. C4 will receive an undisclosed upfront payment and be responsible for the initial development of TPD therapeutics that utilize Degronimid technology for a specific set of target proteins.
Roche will have the option to pursue further clinical development and commercialization following the completion of the preclinical development phase.
Upcoming Events
-
21Oct